Physician profile
Michael A Walby
NPI 1700851631
$1,047.17
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $21.28 · 2021: $214 · 2022: $70.56 · 2023: $70.11 · 2024: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $628.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $127.40 | 2024 | Dextenza |
| Bausch & Lomb Americas INC. | $124.99 | 2024 | Xiidra, Miebo |
| Aerie Pharmaceuticals, INC. | $112.07 | 2019 | |
| Astellas Pharma US INC | $105.76 | 2024 | Izervay |
| Dompe US, INC. | $101.36 | 2024 | Oxervate |
| Coopervision INC. | $99.44 | 2021 | |
| Abbvie INC. | $99.21 | 2024 | |
| Visionix USA, INC | $70.56 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $70.11 | 2023 | Lipiflow System Activator (Disposable) |
| Sun Pharmaceutical Industries INC. | $63.71 | 2021 | |
| Glaukos Corporation | $51.28 | 2021 | |
| Alcon Vision LLC | $21.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Walby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.